Introduction

Miller Fisher syndrome (MFS) is an autoimmune disease that affects the nervous system. It manifests as three main signs: wobbly movements (ataxia), weak eye muscles (ophthalmoplegia), and missing reflexes (areflexia). Doctors see it as a type of Guillain-Barré syndrome (GBS), a bigger group of nerve problems caused by the body attacking itself.¹

Understanding the triggers and underlying causes of MFS is crucial for early detection and effective treatment. MFS is a rare condition, which can lead to initial misdiagnosis or confusion with other disorders. This delay in accurate diagnosis may hinder timely treatment. By exploring and identifying what initiates MFS, we can equip both healthcare professionals and patients with the knowledge needed to recognise it earlier and ensure prompt intervention.

General aetiology of Miller Fisher syndrome

MFS belongs to the range of GBS types, which are self-attacking nerve diseases. We can split this into two parts. In self-attacking disorders, the body's defence system, which guards against harmful outsiders like germs and viruses, targets its own parts. In MFS, this misdirected assault hits the outer nerves messing up their normal job.²

Autoimmune basis

The immune system's dysfunction lies at the core of MFS. This autoimmune response in MFS affects the peripheral nerves causing ataxia (poor movement coordination), ophthalmoplegia (eye muscle paralysis), and areflexia (no tendon reflex). To be able to fully understand the autoimmune basis of MFS, we need to understand molecular mimicry. This is when the immune system meets an antigen (something that triggers an immune response) but it looks similar to a part of the body's own cells. For MFS, antibodies made from infections can also attach to similar molecules on nerve cells starting an autoimmune attack. MFS does not affect everyone exposed to or carrying these infectious agents or antibodies.³

Genetic factors may influence susceptibility in this way. Identification of early signs of MFS and quick responses that can tone down the immune response are crucial.

Infections as triggers

The onset of MFS is often related to infections, as they often initiate the autoimmune response that damages nerves.

Campylobacter jejuni is one of the most common triggering bacteria for MFS. It is frequently responsible for gastroenteritis. Its main symptoms are diarrhoea, stomach cramps, and fever.⁴

The bacterium produces antibodies that can also attach to nerve cell components, mainly the GQ1b ganglioside, because of molecular mimicry, causing the autoimmune response typical of MFS.

The involvement of antibodies in MFS has been extensively recorded. Anti-GQ1b antibodies are usually found in the bloodstream of people with MFS, and are also used as diagnostic criteria. These antibodies stick to the gangliosides on nerve cells, disrupting their normal function and leading to inflammation damage and this disrupts nerve signalling, leading to ataxia, ophthalmoplegia and areflexia.⁵

MFS can also be triggered by other infectious agents such as the Epstein-Barr virus. These viruses trigger an immune response where the antibodies produced to combat the infection mistakenly attack the body's nerve cells. This leads to nerve inflammation and damage, resulting in the common symptoms of MFS.

The time period between symptom manifestation depends on the time needed by the immune system to produce enough antibodies that would impact the nervous system.

Recognising this timeframe relationship is crucial for diagnosing MFS, as patients may not immediately connect their neurological symptoms to a prior infection. 

Genetic predisposition and environmental factors

Genetic predisposition is also important when determining the risk of triggering an autoimmune disease, such as MFS. The human leukocyte antigen (HLA) system is very important in regulating the immune response as certain HLA types are linked with a higher risk of developing MFS since these genetic variations can influence how the immune system reacts to both pathogens and self-antigens.⁶

This is because some HLA types may enhance the immune system's likelihood to produce antibodies that cross-react with self-cells following an infection. This can increase the chances of developing conditions like MFS.

In addition to genetic factors, environmental factors can also contribute to the development of MFS. Certain toxins, chemicals, and pollutants can affect immune system function, thus, these triggers may change immune responses or cause direct damage to nerve cells, creating conditions that are perfect for the onset of autoimmune diseases. Familial incidences of MFS, where multiple family members develop the syndrome, also support the role of genetic and environmental interactions. These suggest that shared genetic factors combined with common environmental exposures within families may contribute to the development of MFS.⁷

Lifestyle factors, such as diet, physical activity level, and overall health, can influence the immune system and influence susceptibility to autoimmune diseases.

Pathogenesis and diagnostic criteria

Pathogenesis

MFS involves a complex interplay between the immune system and the nervous system. Central to this, is the production of auto-antibodies that target the GQ1b ganglioside. These gangliosides are found on the surface of nerve cells and play an important role in nerve function.⁸

The immune-mediated damage disrupts proper function, resulting in the sensory and motor deficits seen in MFS. Inflammation and nerve damage are typically confined to the peripheral nerves, which differentiates MFS from other neurological disorders that may involve the central nervous system.

Diagnostic criteria

Diagnosing MFS is a combination of clinical evaluation, laboratory testing, and sometimes scans. The diagnostic process starts by obtaining a medical history and physical examination. Key symptoms to look for are ataxia, ophthalmoplegia, and areflexia which are classic indicators of MFS.⁹

The most specific test finding of anti-GQ1b antibodies in the blood. Cerebrospinal fluid (CSF) analysis can also provide supportive evidence, as elevated protein levels without an increase in white blood cells (albuminocytologic dissociation) are also common in MFS.

It is also important to differentiate MFS from other GBS variants and neurological disorders through evaluation.

Early and accurate diagnosis of MFS is crucial for effective management and treatment.

Treatment and long-term outlook

Effective management of MFS can significantly improve patient outcomes and quality of life.

Treatment

The primary objective of treating MFS is to effectively manage the autoimmune response and alleviate symptoms. Immunotherapy is the main player here, as it helps regulate the immune system's activity and reduce inflammation. Two commonly utilised immunotherapies are intravenous immunoglobulin (IVIG) and plasmapheresis.

IVIG is the administering of pooled antibodies from healthy donors, which can counteract the detrimental auto-antibodies that attack the peripheral nerves in MFS.¹⁰

Plasmapheresis, also known as plasma exchange, is another viable treatment option. It involves extracting the patient's blood, filtering out the harmful antibodies, and then reintroducing the purified blood back into the body. This process can swiftly diminish auto-antibody levels, which in turn helps alleviate MFS.¹⁰

Physical therapy plays a critical role in helping patients to restore strength, coordination, and mobility. Customised exercise programs can assist in the recovery of muscle function and contribute to overall health improvement.

Patients with ophthalmoplegia may find benefit in specialised eye exercises or the use of prism glasses to correct double vision.

Long-term outlook

The prognosis for individuals with MFS is generally favourable. Most patients experience significant improvement in symptoms within weeks to months following the onset of the syndrome. The majority of individuals achieve near-complete or complete recovery, particularly when timely and appropriate treatment is provided.⁹

However, the recovery process can vary among patients. Complications in MFS are rare but can occur. Persistent neurological deficits, such as chronic muscle weakness or sensory disturbances, may affect a small number of patients but regular follow-up with healthcare providers and continued rehabilitation are important to ensure optimal recovery.

The risk of recurrence of MFS is low, but it can happen so it is best to keep vigilant.

Summary

MFS is a neurological condition recognised  for its symptoms including ataxia, ophthalmoplegia and areflexia. It is categorised as a type of Guillain-Barré Syndrome (GBS), an autoimmune condition in which the peripheral nerves are attacked.

The onset of MFS is associated with a combination of autoimmune responses, genetic predisposition, and environmental factors. Infections like those from Campylobacter jejuni, Cytomegalovirus, and Epstein-Barr virus frequently set off the autoimmune reaction that gives rise to MFS. Certain human leukocyte antigen (HLA) types, as genetic elements, can heighten susceptibility to the syndrome, while exposure to toxins and lifestyle choices also contribute to it.

The focus of MFS development lies in molecular imitation, targeting the GQ1b ganglioside on nerve cells, resulting in inflammation and nerve damage caused by auto-antibodies. Diagnosis of MFS entails clinical evaluation, screening for anti-GQ1b antibodies, and sometimes, examination of cerebrospinal fluid and imaging tests. MFS therapy involves immunotherapy utilising intravenous immunoglobulin (IVIG) or plasmapheresis to reduce the autoimmune response. Symptomatic treatments such as physical therapy and eye exercises aid in alleviating specific symptoms. 

The overall prognosis for MFS is usually positive, as most patients show significant improvement within weeks to months. Continued rehabilitation helps in achieving complete recovery, although some patients may experience lingering symptoms or have a low risk of recurrence.